SAN DIEGO, Aug. 24 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS), a biopharmaceutical company committed to the development and commercialization of novel medicines for the treatment of hepatitis C virus (HCV) infection and cancer, today announced that Steve Worland, Ph.D. has been promoted to the position of President and Chief Executive Officer, replacing Lawrence C. Fritz, Ph.D. who plans to pursue other opportunities. Dr. Worland has also been appointed as a member of the Company's Board of Directors.
Dr. Worland joined Anadys in March 2001 as Chief Scientific Officer and most recently served as President, Pharmaceuticals. Prior to joining the Company, Dr. Worland was Vice President, Head of Antiviral Research, at Agouron Pharmaceuticals, a Pfizer Company and was also a Vice President at Warner-Lambert prior to the acquisition by Pfizer.
"We are pleased to appoint Steve as President and CEO," said George A. Scangos, Ph.D., Chairman of the Board. "Steve has been intimately involved in building Anadys since its early days, knows the ANA773 and ANA598 programs in detail, and has the right skills and experience to lead the Company as it pursues the development of these two programs. The current focus for Anadys is to aggressively advance these projects, focus on execution and meet our objectives. Steve, who has evolved into a business and scientific leader, is perfectly positioned to lead the Company in pursuit of these goals. We remain on track to file an IND for ANA773 this year and an IND for ANA598 in the first half of 2008."
"I would like to thank Larry for his service and contributions to
Anadys and wish him well with his future endeavors," added Dr. Scangos.
"Larry has p
|SOURCE Anadys Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved